Detalhe da pesquisa
1.
Mass Spectrometry-Based Assessment of M-protein in Peripheral Blood During Maintenance Therapy in Multiple Myeloma.
Blood
; 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38713888
2.
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study.
Haematologica
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38426292
3.
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Lancet Oncol
; 24(2): 139-150, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36642080
4.
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.
Br J Haematol
; 203(5): 792-802, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37691005
5.
The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.
Int J Mol Sci
; 24(3)2023 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36769265
6.
An elevated systemic inflammation index is related to an inferior response to pomalidomide and dexamethasone treatment in patients with relapsed and refractory multiple myeloma.
Contemp Oncol (Pozn)
; 27(3): 139-146, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38239862
7.
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Eur J Haematol
; 108(1): 73-83, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496096
8.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Lancet
; 396(10262): 1563-1573, 2020 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33189178
9.
The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications.
Int J Mol Sci
; 22(21)2021 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34769503
10.
Bone lesions in hairy cell leukemia: Diagnosis and treatment.
Eur J Haematol
; 105(6): 682-691, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32757401
11.
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma.
Am J Hematol
; 95(5): 503-509, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32072687
12.
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
Future Oncol
; 16(11): 631-641, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32141766
13.
Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib.
Mediators Inflamm
; 2020: 1835836, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32587468
14.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 20(6): 781-794, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31097405
15.
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.
Br J Haematol
; 180(6): 831-839, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29315478
16.
Emerging antibody-drug conjugates for treating lymphoid malignancies.
Expert Opin Emerg Drugs
; 22(3): 259-273, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28792782
17.
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.
Br J Haematol
; 175(5): 884-891, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27682187
18.
Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis.
Haematologica
; 106(2): 601-604, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32381580
19.
Multifocal osteolytic lesions in hairy cell leukemia-the importance of PET/CT in diagnosis and assessment.
Ann Hematol
; 100(6): 1641-1645, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32533250
20.
Emerging immunological drugs for chronic lymphocytic leukemia.
Expert Opin Emerg Drugs
; 20(3): 423-47, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26153226